ALVOTECH financials
Also U.S.-listed. ALVOTECH is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: ALVO — ALVOTECH
ALVOTECH
Country: IS Reporting currency: USD Latest annual report: 2025-12-31
LEI:
222100DCZBOWV5DZ8372 Financial statements
(USD, as reported — unscaled; 102 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Other income | $2.6M | $2.3M |
| Operating profit (EBIT) | $78.2M | $69.6M |
| Finance costs | $149.2M | $303.2M |
| Profit before tax | $136.3M | -$217.6M |
| Income tax expense | $108.4M | $14.3M |
| Profit for the year | $27.9M | -$231.9M |
| Total comprehensive income | $31.5M | -$232.6M |
| Per share | ||
| Basic EPS | $0.10 | $-0.87 |
| Free cash flow / share | $-0.41 | $-1.09 |
| Cash flow statement | ||
| Cash generated from operations | $7.1M | -$184.5M |
| Net cash from operating activities | -$50.2M | -$236.8M |
| Income taxes paid | $780.0K | $2.0M |
| Net cash from investing activities | -$104.2M | -$18.9M |
| Purchase of PP&E (capex) | $64.5M | $53.7M |
| Purchase of intangibles | $31.7M | $3.3M |
| Net cash from financing activities | $270.8M | $297.3M |
| Proceeds from borrowings | $233.5M | $896.3M |
| Repayments of borrowings | $25.4M | $749.1M |
| Lease liability payments | $10.4M | $10.2M |
| Net change in cash | $116.4M | $41.6M |
| Balance sheet | ||
| Total assets | $1.49B | $1.22B |
| Non-current assets | $913.1M | $766.4M |
| Property, plant & equipment | $356.4M | $284.5M |
| Right-of-use assets | $138.3M | $125.2M |
| Intangible assets & goodwill | $12.8M | $11.3M |
| Current assets | $574.0M | $455.0M |
| Inventories | $220.1M | $127.9M |
| Trade & other receivables | $69.7M | $160.2M |
| Cash & equivalents | $172.4M | $51.4M |
| Total equity | -$284.5M | -$412.8M |
| Non-current liabilities | $1.47B | $1.44B |
| Long-term borrowings | $1.26B | $1.04B |
| Lease liabilities (non-current) | $138.0M | $112.1M |
| Current liabilities | $304.1M | $193.4M |
| Lease liabilities (current) | $12.1M | $9.5M |
| Deferred tax liabilities | $7.9M | $1.8M |
| Derived metrics | ||
| Free cash flow | -$114.7M | -$290.5M |
| Operating margin | 25.2% | 32.2% |
| Net margin | 9.0% | -107.2% |
| Return on equity | -9.8% | 56.2% |
| Cash conversion ratio | -1.80× | 1.02× |
| Capex coverage | -0.78× | -4.41× |
| Other reported items | ||
| Adjustments For Decrease Increase In Contract Assets | -$94.9M | -$45.2M |
| Adjustments For Decrease Increase In Inventories | -$90.1M | -$50.0M |
| Adjustments For Decrease Increase In Other Assets | -$4.2M | -$7.1M |
| Adjustments For Decrease Increase In Trade Account Receivable | $93.2M | -$119.1M |
| Adjustments For Depreciation and Amortisation Expense | $37.9M | $31.3M |
| Adjustments For Finance Costs | $149.2M | $303.2M |
| Adjustments For Finance Income | $198.5M | $80.1M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | $646.0K | -$3.5M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | $703.0K | -$946.0K |
| Adjustments For Income Tax Expense | $108.4M | $14.3M |
| Adjustments For Increase Decrease In Contract Liabilities | -$69.3M | -$31.4M |
| Adjustments For Increase Decrease In Other Liabilities | $5.1M | -$14.3M |
| Adjustments For Increase Decrease In Trade and Other Payables | $45.3M | -$13.7M |
| Adjustments For Sharebased Payments | $7.4M | $7.6M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | $16.8M | -$8.2M |
| Cash Advances and Loans From Related Parties | $0 | $24.5M |
| Cash Flows From Used In Operations Before Changes In Working Capital | $124.8M | $104.1M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $14.0M | $0 |
| Cash Repayments of Advances and Loans From Related Parties | $0 | $9.5M |
| Cost of Merchandise Sold | $235.6M | $185.3M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | $36.9M | $32.7M |
| Current Contract Assets | $64.4M | $67.3M |
| Current Contract Liabilities | $30.4M | $16.0M |
| Current Tax Liabilities Current | $1.0M | $204.0K |
| Deferred Tax Assets | $192.2M | $298.4M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | $4.5M | -$1.3M |
| Equity and Liabilities | $1.49B | $1.22B |
| Finance Income | $198.5M | $80.1M |
| Gain Loss Arising From Difference Between Carrying Amount of Financial Liability Extinguished and Consideration Paid | $17.7M | -$69.4M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -$16.8M | $8.2M |
| General and Administrative Expense | $90.9M | $65.7M |
| Increase Decrease Through Conversion of Convertible Instruments | — | $264.0M |
| Increase Decrease Through Exercise of Options | $347.0K | $276.0K |
| Increase Decrease Through Sharebased Payment Transactions | $7.0M | $6.5M |
| Intangible Assets Other Than Goodwill | $81.8M | $20.6M |
| Interest Paid Classified As Operating Activities | $59.0M | $54.9M |
| Interest Received Classified As Operating Activities | $2.4M | $4.6M |
| Issue of Equity | $78.3M | $144.6M |
| Issued Capital | $2.9M | $2.8M |
| Liabilities | $1.77B | $1.63B |
| Noncurrent Contract Assets | $122.9M | $22.7M |
| Noncurrent Contract Liabilities | $5.5M | $80.7M |
| Noncurrent Derivative Financial Liabilities | $54.0M | $210.2M |
| Other Cash Receipts From Sales of Interests In Joint Ventures Classified As Investing Activities | $6.0M | $12.0M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | $3.6M | -$690.0K |
| Other Current Assets | $47.0M | $48.1M |
| Other Current Liabilities | $94.2M | $59.4M |
| Other Noncurrent Assets | $8.6M | $3.6M |
| Payments For Share Issue Costs | $3.8M | $5.8M |
| Proceeds From Exercise of Options | $0 | $76.0K |
| Proceeds From Exercise of Warrants | $0 | $4.8M |
| Proceeds From Issuing Shares | $82.5M | $150.5M |
| Research and Development Expense | $184.2M | $171.3M |
| Reserve of Exchange Differences On Translation | $1.4M | -$2.2M |
| Retained Earnings | -$2.41B | -$2.44B |
| Revenue From Contracts With Customers | $310.1M | $216.2M |
| Revenue From Sale of Goods | $276.3M | $273.5M |
| Share Premium | $2.11B | $2.01B |
| Trade and Other Current Payables To Related Parties | $3.3M | $8.5M |
| Trade and Other Current Receivables Due From Related Parties | $438.0K | $118.0K |
Methodology
Every line item above is a fact tagged in ALVOTECH's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.